Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

AML
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Sarcoma
Skin Cancers
Thyroid Cancers

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

Biosimilars MORE >>

Pegfilgrastim Biosimilar Approved by FDA
November 06, 2018
Pegfilgrastim-cbqv (CHS-1701; Udencya), a pegfilgrastim (Neulasta) biosimilar, has been granted approval by the FDA for patients with cancer receiving myelosuppressive chemotherapy.
Read more >>
Expert Panel Discusses the Financial and Economic Impact of Biosimilars
November 01, 2018
Trastuzumab Biosimilar Candidate Shows Promise in Early-Stage Breast Cancer
August 30, 2018
Second Filgrastim Biosimilar Granted FDA Approval
July 24, 2018
PFS With MYL-1401O Regimen Similar to Trastuzumab at 48 Weeks in HER2-Positive Metastatic Breast Cancer
June 08, 2018

VideosMORE >>

Impact of Biosimilars on Oncology

Latest JournalAll Journals >>

Evolving Paradigms Non-Small Cell Lung Cancer
Evolving Paradigms
Dr. Langer Discusses the Prevalence of Patients With Non-Driver NSCLC
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
Nonbiomarker, Nonsquamous NSCLC: Diagnosis, Statistics, Staging, and Testing
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLC
Emerging Treatment Strategies in Nonsquamous NSCLC
MORE >>
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.